Cancer Epidemiology Biomarkers & Prevention, Vol 5, Issue 8 657-666, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives

GJ Kelloff, JR Fay, VE Steele, RA Lubet, CW Boone, JA Crowell and CC Sigman
Chemoprevention Branch, Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Maryland 20892, USA.

Among the most important targets for chemopreventive intervention and drug development are deregulated signal transduction pathways, and protein tyrosine kinases are key components of these pathways. Loss of tyrosine kinase regulatory mechanisms has been implicated in neoplastic growth; indeed, many oncogenes code for either receptor or cellular tyrosine kinases. Because of its deregulation in many cancers (bladder, breast, cervix, colon, esophagus, head and neck, lung, and prostate), the epidermal growth factor receptor (EGFR) has been selected as a potential target for chemoprevention. Because growth factor networks are redundant, selective inhibition of signaling pathways activated in precancerous and cancerous cells should be possible. Requirements for specific EGFR inhibitors include specificity for EGFR, high potency, activity in intact cells, and activity in vivo. Inhibition of autophosphorylation is preferred, because it should result in total blockade of the signaling pathway. Inhibitors that compete with substrate rather than at the ATP-binding site are also preferable, because they are not as likely to inhibit other ATP-using cellular enzymes. Several classes of specific EGFR inhibitors have been synthesized recently, including structures such as benzylidene malononitriles, dianilinophthalimides, quinazolines, pyrimidines, [(alkylamino)methyl]-acrylophenones, enollactones, dihydroxybenzylaminosalicylates, 2-thioindoles, aminoflavones, and tyrosine analogue-containing peptides. A possible testing strategy for the development of these and other EGFR inhibitors as chemopreventive agents includes the following steps: (a) determine EGFR tyrosine kinase inhibitory activity in vitro; (b) evaluate EGFR specificity and selectivity (relative to other tyrosine kinases and other protein kinases); (c) determine inhibition of EGFR-mediated effects in intact cells; (d) determine inhibition of EGFR-mediated effects in vivo (e.g., in nude mouse tumor xenografts); and (e) determine chemopreventive efficacy in vivo (e.g., in the hamster buccal pouch or mouse or rat bladder).

This article has been cited by other articles:

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				D Wang and R N DuBois PROSTAGLANDINS AND CANCER Gut, January 1, 2006; 55(1): 115 - 122. [Full Text] [PDF]

				J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896. [Full Text] [PDF]

				D. Wang and R. N. DuBois Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch PNAS, January 13, 2004; 101(2): 415 - 416. [Full Text] [PDF]

				R. S. Herbst and P. A. Bunn Jr. Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5813 - 5824. [Abstract] [Full Text] [PDF]

				G. Vlahovic and J. Crawford Activation of Tyrosine Kinases in Cancer Oncologist, December 1, 2003; 8(6): 531 - 538. [Abstract] [Full Text] [PDF]

				J. Stamos, M. X. Sliwkowski, and C. Eigenbrot Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor J. Biol. Chem., November 22, 2002; 277(48): 46265 - 46272. [Abstract] [Full Text] [PDF]

				A. Hirata, S.-i. Ogawa, T. Kometani, T. Kuwano, S. Naito, M. Kuwano, and M. Ono ZD1839 (Iressa) Induces Antiangiogenic Effects through Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Res., May 1, 2002; 62(9): 2554 - 2560. [Abstract] [Full Text] [PDF]

				R. N. DuBois New paradigms for cancer prevention Carcinogenesis, May 1, 2001; 22(5): 691 - 692. [Full Text] [PDF]

				S. R. Ritland, S. J. Gendler, L. J. Burgart, D. W. Fry, J. M. Nelson, A. J. Bridges, L. Andress, and W. E. Karnes Jr. Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase Fails to Suppress Adenoma Formation in ApcMin Mice but Induces Duodenal Injury Cancer Res., September 1, 2000; 60(17): 4678 - 4681. [Abstract] [Full Text]

				K.-W. Chang, S. Sarraj, S.-C. Lin, P.-I Tsai, and D. Solt p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis Carcinogenesis, July 1, 2000; 21(7): 1441 - 1451. [Abstract] [Full Text] [PDF]

				T. J. Kottke, A. L. Blajeski, L. M. Martins, P. W. Mesner Jr., N. E. Davidson, W. C. Earnshaw, D. K. Armstrong, and S. H. Kaufmann Comparison of Paclitaxel-, 5-Fluoro-2'-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis. EVIDENCE FOR EGF-INDUCED ANOIKIS J. Biol. Chem., May 28, 1999; 274(22): 15927 - 15936. [Abstract] [Full Text] [PDF]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]

				H. Jinno, M. G. Steiner, R. G. Mehta, M. P. Osborne, and N. T. Telang Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide Carcinogenesis, February 1, 1999; 20(2): 229 - 236. [Abstract] [Full Text] [PDF]